Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

199 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Hypersensitivity/ Anaphylaxis Evaluation Mepolizumab HES NCT00086658 - Hypersensitivity/ Anaphylaxis Evaluation

- 20/09/2021 - 1 modulo, 1 ItemGroup, 53 elementi, 1 linguaggio
ItemGroup: evaluation Hypersensitivity
Study part: Hypersensitivity/ Anaphylaxis Evaluation.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Notification Form (Subject) Week 36 Mepolizumab HES NCT00086658 - Pregnancy Notification Form (Subject) Week 36

- 15/07/2017 - 1 modulo, 3 itemgroups, 44 elementi, 1 linguaggio
Itemgroups: Family history mother, Family history father, information investigator
Study part: Pregnancy Notification Form (Subject) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Follow- Up Form- Current Pregnancy Information Week 36 Mepolizumab HES NCT00086658 - Pregnancy Follow- Up Form- Current Pregnancy Information Week 36

- 15/07/2017 - 1 modulo, 5 itemgroups, 39 elementi, 1 linguaggio
Itemgroups: FOLLOW-UP Pregnancy, INFANT INFORMATION, PREGNANCY INFORMATION, drug exposures pregnancy, information investigator
Study part: Pregnancy Follow- Up Form- Current Pregnancy Information Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 36 Mepolizumab HES NCT00086658 - Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 36

- 15/07/2017 - 1 modulo, 1 ItemGroup, 7 elementi, 1 linguaggio
ItemGroup: SAE
Study part: Serious Adverse Event (SAE)- Additional/ Follow- Up Information Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Rotterdem Symptom Checklist (RSCL) Week 36 Mepolizumab HES NCT00086658 - Rotterdem Symptom Checklist (RSCL) Week 36

- 15/07/2017 - 1 modulo, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: Symptom checklist
Study part: Rotterdem Symptom Checklist (RSCL) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Your Health and Well- Being Week 36 Mepolizumab HES NCT00086658 - Your Health and Well- Being Week 36

- 15/07/2017 - 1 modulo, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: Health assessment questionnaire score quality of life
Study part: Your Health and Well- Being Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Subject contact Safety follow-up visit Mepolizumab HES NCT00086658 - Subject contact Safety follow-up visit

- 15/07/2017 - 1 modulo, 1 ItemGroup, 4 elementi, 1 linguaggio
ItemGroup: CONTACT
Study part: Subject contact Safety follow-up visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pruritus Visual Analogue Scale (VAS) Week 36 Mepolizumab HES NCT00086658 - Pruritus Visual Analogue Scale (VAS) Week 36

- 15/07/2017 - 1 modulo, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: Assessment using visual analog scale Pruritus
Study part: Pruritus Visual Analogue Scale (VAS) Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Urine Pregnancy Test Prompt Safety follow-up visit Mepolizumab HES NCT00086658 - Urine Pregnancy Test Prompt Safety follow-up visit

- 15/07/2017 - 1 modulo, 1 ItemGroup, 2 elementi, 1 linguaggio
ItemGroup: Urine Pregnancy Test
Study part: Urine Pregnancy Test Prompt Safety follow-up visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pharmacokinetics- Blood Week 38 Mepolizumab HES NCT00086658 - Pharmacokinetics- Blood Week 38

- 15/07/2017 - 1 modulo, 1 ItemGroup, 4 elementi, 1 linguaggio
ItemGroup: Pharmacokinetics Blood
Study part: Pharmacokinetics- Blood Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Adverse events Safety follow-up visit Mepolizumab HES NCT00086658 - Adverse events Safety follow-up visit

- 15/07/2017 - 1 modulo, 1 ItemGroup, 1 elemento, 1 linguaggio
ItemGroup: Adverse Events
Study part: Adverse events Safety follow-up visit. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Exploratory Biomarker Research Week 38 Mepolizumab HES NCT00086658 - Exploratory Biomarker Research Week 38

- 15/07/2017 - 1 modulo, 1 ItemGroup, 4 elementi, 1 linguaggio
ItemGroup: Biomarker
Study part: Exploratory Biomarker Research Week 38 / Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial